Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,043 mentions
- robotic manipulationmarket824 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology491 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology371 mentions
- agentic AItechnology353 mentions
- vision-language-action modeltechnology350 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Vision-Language Modeltechnology318 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology175 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology169 mentions
- IBMorganization163 mentions
Entity
ATR-COSF
product4 mentionslast seen Nov 10, 2026
Recombinant protein technology designed for cosmetic and skincare applications.
Relationships 6
- Azitra, Inc.developsATR-COSF99% confidence4 sources
- ATR-COSFcomposed offilaggrin recombinant protein93% confidence1 source
- ATR-COSFdepends onS. epidermidis engineering91% confidence1 source
- ATR-COSFapplies toanti-aging cosmetics90% confidence1 source
- ATR-COSFapplies toskincare and cosmetics90% confidence1 source
- ATR-COSFdepends onfilaggrin domain delivery88% confidence1 source
Relationship
Azitra, Inc.developsATR-COSF
99% confidence4 supporting mentions
Either name opens that entity’s relationships.
Sources 4
- filingSEC EDGARNov 10, 2026Azitra, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Azitra, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and novel products across therapeutics, cosmeceuticals and biotechnology applications. The Company's portfolio is highlighted by ATR-COSF, a recombinant protein technology designed for cosmetic and skincare applications
- filingSEC EDGAROct 29, 2026Azitra, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
The Company's portfolio is highlighted by ATR-COSF, a recombinant protein technology
- filingSEC EDGAROct 26, 2026Azitra, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and high value cosmetic proteins and peptides, today announced that Cofounder and Chief Operating Officer, Travis Whitfill, PhD, MPH, will present progress for its cosmetic ATR-COSF program
- filingSEC EDGAROct 1, 2026Azitra, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
The Company's portfolio is highlighted by ATR-COSF, a recombinant protein technology designed for cosmetic and skincare applications